AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designati
ABBV: AbbVie Inc. 2022-01-04 08:15:00 AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer